



P&T MEETING AGENDA: JULY 28, 2026



COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, July 28, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
Microsoft Teams Join the meeting now Meeting ID: 285 749 030 599 24 Passcode: tK9At9uC Download Teams Join on the web	+1 858-252-2734 (United States) Phone conference ID: 979 443 568#

AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (Upon Request)**
- III. **Old Business**
 - a. Approval of April 2026 Meeting Minutes
- IV. **New Business**
 - a. New Products to Market to be Reviewed as Single Products
 - i. Yuviwel® (navepegritide) – Non-PDL
 - ii. Icotyde™ (icotrokinra) – Non-PDL
 - iii. Kygevvi® (doxecitine and doxribtimine) – Non-PDL
 - iv. Nereus™ (tradipitant) – Gastrointestinal: Antiemetics and Antivertigo Agents: Non-Preferred
 - v. Idvynso™ (doravirine/islatravir) – Antiretrovirals: HIV/AIDS: Non-Preferred
 - vi. Bysanti™ (milsaperidone) – Central Nervous System: Antipsychotics Second-Generation (Atypical): Non-Preferred
 - vii. Baxfendy™ (baxdrostat) – Non-PDL
 - b. Vraylar® (cariprazine) – Proposed Prior Authorization Criteria Update
- V. **Therapeutic Classes with Recommended PDL Status Changes**
 - a. Angiotensin-Converting Enzyme (ACE) Inhibitors
 - b. Angiotensin Receptor Blockers (ARBs)
 - c. Antiarrhythmics, Oral
 - d. Anticoagulants
 - e. Anticonvulsants





- f. Antidepressants, Tricyclics
- g. Calcium Channel Blockers (CCBs)
- h. Movement Disorders
- i. Narcolepsy Agents
- j. Platelet Aggregation Inhibitors
- k. Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled
- l. Stimulants and Related Agents

VI. Consent Agenda

- a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

• 5-Alpha Reductase (5AR) Inhibitors • ACEI + Diuretic Combinations • Alpha Blockers for Benign Prostatic Hyperplasia (BPH) • Alzheimer's Agents • Angiotensin Modulator + Calcium Channel Blocker (CCB) Combinations • Anti-anginal and Anti-Ischemic • Antidepressants, Monoamine Oxidase Inhibitors (MAOIs) • Antidepressants, Other • Antidepressants, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) • Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs) • Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Acute Treatment • Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Prophylaxis, Injectable	• Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Prophylaxis, Oral • Antimigraine Agents, Triptans • Antiparkinson's Agents • Antipsychotics • Anxiolytics • ARB + Diuretic Combinations • Beta-Blockers • Bladder Relaxants • Direct Renin Inhibitors • Dopamine Receptor Agonists • Lipotropics, Other • Lipotropics, Statins • Neuropathic Pain • Sedative Hypnotics • Skeletal Muscle Relaxants • Spinal Muscular Atrophy • Tobacco Cessation Products
--	--

VII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. October 13, 2026





P&T MEETING AGENDA: JULY 28, 2026



To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.

